Creo signs commercialisation agreement
Creo Medical Group has signed a commercialisation agreement with the Department of Health and Social Care to provide NHS Hospitals with access to one its products at preferential rates for a limited period.
The medical device company said the agreement relates to its CROMA Advanced Energy Platform and associated devices for use in gastrointestinal therapeutic endoscopy.
The National Institute for Health Research (NIHR) Invention for Innovation (“i4i”) Programme supported certain development projects that Creo undertook via a series of funding awards between 2010 and 2015, totalling close to £2m.
In accordance with the terms of such funding, Creo has entered into this commercialisation agreement, which is designed to aid the roll-out of CROMA and accompanying consumable GI devices in the UK. The agreement also provides for training for clinicians and nurses on the use of Creo’s suite of advanced energy surgery products.
Creo chief executive Craig Gulliford said: “We are delighted to reach a commercialisation agreement with the Department of Health and Social Care which will enable us to roll-out our game-changing devices throughout the NHS, empowering endoscopists and surgeons to change the way they operate bringing significant benefits to their patients.
“We are hugely grateful for the support of NIHR in the development of our CROMA platform and suite of devices and look forward to increasing the adoption of our products in our home market.”